Metabolite profiling for upper aerodigestive tract cancer
Official title: Metabolomics of Cancers of the Upper Aerodigestive Tract
Run by Centre Antoine Lacassagne · NCT07377084 · Data updated 2026-11-12
This research will test whether blood and urine metabolite patterns can identify and characterize upper aerodigestive tract cancers in people with newly diagnosed, untreated squamous cell tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Centre Antoine Lacassagne Academic / other |
| Locations | 1 site (Nice) |
| Status | Recruiting |
| Started | November 4, 2020 |
| Main results expected | February 2026 |
| Study ends | May 2027 |
| Registry record updated | January 29, 2026 |
| Trial ID | NCT07377084 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with histologically confirmed, untreated squamous cell carcinoma of the upper aerodigestive tract (T1-4, N0-3, M0) who are planned for curative treatment at Centre Antoine Lacassagne and consent to provide blood and urine samples.
✕Probably not a fit
Patients with metastatic (M1) disease, those not eligible for curative treatment, or those unwilling to allow the use of their biological samples are unlikely to benefit from this research.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project uses mass spectrometry-based metabolomics on blood and urine samples from patients with untreated squamous cell cancers of the oral cavity, oropharynx, larynx, or hypopharynx. Researchers will measure small-molecule metabolites and apply statistical and machine-learning methods to look for signatures that distinguish tumor types, HPV-related disease, and clinical features like stage or treatment response. No experimental treatment is given; participation involves sample collection and data use alongside planned curative care at Centre Antoine Lacassagne. Findings will be compared with clinical and pathological data to develop potential biomarkers for early detection, monitoring, and recurrence surveillance.
Why it matters
Potential benefit: If successful, this could lead to quick, low-cost blood or urine tests that help detect UADT cancers earlier and monitor treatment response or recurrence.
How similar studies have gone: Metabolomics has produced useful biomarkers in other cancer types, but no published metabolomic studies specific to upper aerodigestive tract cancers have been reported, so this application is largely novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven squamous cell carcinoma of the upper aerodigestive tract (oral cavity, oropharynx, larynx, and hypopharynx), stage T1-4, N0-3, M0, untreated. * Curative treatment planned at CAL. * Patient who has voluntarily consented to the use of their data and signed a non-opposition form for the use of their biological and tumor samples. Exclusion Criteria: * Metastatic patient (M1). * No curative treatment possible. * History of cancer (other than basal cell carcinoma) in the last 5 years. * Tumor size deemed insufficient according to the assessment of the ENT surgeon. * Patient refusal to allow the use of their biological and tumor samples for research. * Vulnerable persons are defined in articles L1121-5 to -8: * Pregnant women, women in labor, and nursing mothers, individuals deprived of liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of article L. 1121-8, * And individuals admitted to a health or social establishment for purposes other than research, * Adults under legal protection or unable to express their non-opposition.
Where it's running
-
Centre Antoine Lacassagne
Nice, France Recruiting
Study contacts
- Principal investigator: Alexandre BOZEC, MD — Centre Antoine Lacassagne
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adherence to a Remote Physical Activity Program on a Smartwatch and its Effect on Fatigue After Adjuvant Chemotherapy
This study tests whether sticking with an adapted physical activity program tracked on a smartwatch can reduce fatigue in adults who have finished adjuvant chemotherapy for certain cancers.
-
Research on biomarkers for cancer treatment response and survival
This study is trying to find markers in blood samples that can help predict how well cancer patients will respond to treatment and how long they might live.
-
Evaluating PET scans for predicting treatment response in lung cancer patients
This study is testing if PET scans can help predict how well lung cancer patients will respond to immunotherapy, with or without chemotherapy.
-
Creating tumor models to test new cancer treatments
This study is trying to see how well new cancer treatments work on tumor samples from patients with specific mutations.
-
Adding a CyberKnife boost after chemoradiation for locally advanced non-small-cell lung cancer
This trial will try giving a targeted CyberKnife radiation boost after standard platinum-based induction and concurrent chemoradiation to see if it improves outcomes for adults with unresectable stage III non-small-cell lung cancer.
-
Evaluating liquid biopsy for cancer diagnosis
This study tests if a blood test that looks for cancer DNA can help doctors find problems in patients with advanced cancer, comparing it to the usual tissue tests.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.